• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Prostate-Specific Gene Therapy Using a 'Gutless' Adeno-Vector Expressing Antisense TGF-Beta and PSA Promoter-Controlled TNF-Alpha Gene.
【24h】

Prostate-Specific Gene Therapy Using a 'Gutless' Adeno-Vector Expressing Antisense TGF-Beta and PSA Promoter-Controlled TNF-Alpha Gene.

机译：前列腺特异性基因治疗使用表达反义TGF-β和psa启动子控制的TNF-α基因的'Gutless'腺病毒载体。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The goal of this research has been to develop an immune-based gene therapy that combines targeted cytotoxicity with reversal of local tumor immune suppression to eradicate prostate cancer cells. Reversal of local tumor immune suppression was achieved in vitro by blocking the over expression of TGF-beta2 produced by prostate cancer cells using TGF-beta2 phosphorothinate oligonucleotide antisense. We have been developing a gutless adenovector with extended transgene expression that we think will have enhanced safety for pre- clinical and clinical use. Our gutless adenovector DNA backbone contains the cytotoxic gene under the control of an improved prostate specific promoter and a marker GFP gene for detection in in vivo studies. Our improved PSA promoter/ enhancer presents 19-fold higher transcriptional activity compared to native PSA promoter/enhancer and has no loss of tissue specificity. Using Apo2L/TRAlL, a TNF-a related cytokine with less systemic toxicity, we have demonstrated selective cytotoxicity in our highly aggressive androgen-independent prostate cancer cell line (CL1). Further in vivo studies are being conducted to evaluate the overall efficacy and safety of Apo2L/TRAIL gene therapy in combination with TGF-beta2 antisense for prostate cancer treatment.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号